TY - JOUR T1 - Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol JF - Canadian Medical Association Journal JO - CMAJ SP - 577 LP - 583 VL - 124 IS - 5 AU - C. Velentzas AU - D. G. Oreopoulos AU - A. Pierratos AU - H. E. Meema AU - S. Rabinovich AU - H. Meindok AU - H. Husdan AU - T. M. Murray AU - R. Ogilvie AU - A. Katirtzoglou Y1 - 1981/03/01 UR - http://www.cmaj.ca/content/124/5/577.abstract N2 - Nine patients with renal osteodystrophy were tested for 6.5 to 35 months with 1,25-dihydroxycholecalciferol (1,25-DHCC). A close biochemical follow-up was performed during the first 6 months of treatment, including biweekly determinations of serum calcium, phosphorus, magnesium, alkaline phosphatase and creatinine levels. A bone biopsy, radiologic investigations and determinations of plasma levels of immunoreactive parathyroid hormone (IPTH) and intestinal absorption of calcium 47 were performed before and after the 6 months. Although the five patients with osteitis fibrosa showed a significant improvement, the four with predominantly osteomalacic lesions showed no response to treatment. These four had a normal initial plasma iPTH level, higher serum calcium levels than the other five patients, extreme sensitivity to 1,25-DHCC, with frequent episodes of hypercalcemia, and only a slightly increased serum alkaline phosphatase level, which remained unchanged during treatment. All but one of the patients, irrespective of the histologic abnormality, showed a decrease in the uptake of radionuclide by bone after treatment. The renal function of one patient, a man with long-standing stable renal failure who had not undergone dialysis, deteriorated during treatment. ER -